0.585
0.01 (0.86%)
| Penutupan Terdahulu | 0.580 |
| Buka | 0.600 |
| Jumlah Dagangan | 67,254 |
| Purata Dagangan (3B) | 207,102 |
| Modal Pasaran | 64,512,044 |
| Harga / Jualan (P/S) | 92.40 |
| Harga / Buku (P/B) | 2.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 21 Aug 2024 |
| Margin Operasi (TTM) | -259.14% |
| EPS Cair (TTM) | -0.070 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -1.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.02% |
| Nisbah Semasa (MRQ) | 7.07 |
| Aliran Tunai Operasi (OCF TTM) | -4.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.05 M |
| Pulangan Atas Aset (ROA TTM) | -19.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.10% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (AU) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Bercampur | Bercampur | |
| Stok | INOVIQ LTD FPO [IIQ] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.63 |
|
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 27.72% |
| % Dimiliki oleh Institusi | 10.49% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |